- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
51
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
51 companies
Madrigal Pharmaceuticals
Market Cap: US$11.3b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$541.50
7D
21.8%
1Y
59.7%
Arcutis Biotherapeutics
Market Cap: US$2.9b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$24.03
7D
0.08%
1Y
134.4%
Syndax Pharmaceuticals
Market Cap: US$1.4b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$17.73
7D
15.5%
1Y
9.4%
Caris Life Sciences
Market Cap: US$7.0b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$25.16
7D
-19.3%
1Y
n/a
Mereo BioPharma Group
Market Cap: US$281.6m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$1.87
7D
5.1%
1Y
-54.4%
Legend Biotech
Market Cap: US$5.8b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$32.03
7D
-0.06%
1Y
-20.3%
Achieve Life Sciences
Market Cap: US$227.4m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.77
7D
-0.8%
1Y
2.6%
Capricor Therapeutics
Market Cap: US$254.2m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$6.20
7D
2.3%
1Y
-65.7%
RenovoRx
Market Cap: US$36.5m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.07
7D
4.9%
1Y
-2.3%
ARS Pharmaceuticals
Market Cap: US$877.8m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$8.77
7D
0.7%
1Y
-47.2%
Tenaya Therapeutics
Market Cap: US$233.1m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$1.42
7D
2.9%
1Y
-35.7%
Soleno Therapeutics
Market Cap: US$2.5b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$48.70
7D
-23.7%
1Y
-15.0%
Lineage Cell Therapeutics
Market Cap: US$415.6m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.82
7D
0%
1Y
99.3%
OS Therapies
Market Cap: US$63.4m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$1.89
7D
5.0%
1Y
-25.0%
Aldeyra Therapeutics
Market Cap: US$308.6m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.23
7D
6.3%
1Y
10.0%
Longeveron
Market Cap: US$15.8m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.72
7D
-10.4%
1Y
-68.8%
Viridian Therapeutics
Market Cap: US$2.6b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$28.43
7D
26.1%
1Y
26.7%
AC Immune
Market Cap: US$331.5m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.39
7D
2.7%
1Y
10.8%
TuHURA Biosciences
Market Cap: US$124.1m
A clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies.
HURA
US$2.38
7D
-2.9%
1Y
-51.8%
Altimmune
Market Cap: US$444.1m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$4.28
7D
13.8%
1Y
-54.9%
XOMA Royalty
Market Cap: US$404.8m
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
XOMA
US$34.49
7D
6.2%
1Y
10.3%
NewAmsterdam Pharma
Market Cap: US$4.4b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
NAMS
US$39.89
7D
9.2%
1Y
61.1%
Insmed
Market Cap: US$40.9b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$193.69
7D
6.0%
1Y
176.1%
BioRestorative Therapies
Market Cap: US$11.9m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.41
7D
-3.4%
1Y
-14.0%
Anavex Life Sciences
Market Cap: US$557.5m
Operates as a biopharmaceutical company.
AVXL
US$6.85
7D
-8.3%
1Y
-24.1%
Unicycive Therapeutics
Market Cap: US$83.2m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$4.79
7D
7.9%
1Y
-1.1%
Rezolute
Market Cap: US$923.1m
A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
RZLT
US$10.04
7D
12.8%
1Y
72.5%
Marker Therapeutics
Market Cap: US$12.5m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$0.93
7D
3.3%
1Y
-75.0%
uniQure
Market Cap: US$1.6b
Develops treatments for patients suffering from rare and other devastating diseases in the United States.
QURE
US$30.84
7D
1.3%
1Y
358.2%
Ardelyx
Market Cap: US$1.4b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.13
7D
9.5%
1Y
33.6%
Rhythm Pharmaceuticals
Market Cap: US$6.7b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$99.86
7D
0.4%
1Y
66.2%
Creative Medical Technology Holdings
Market Cap: US$12.1m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$3.20
7D
12.4%
1Y
16.0%
Day One Biopharmaceuticals
Market Cap: US$1.0b
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$10.36
7D
41.9%
1Y
-33.8%
Ionis Pharmaceuticals
Market Cap: US$11.3b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$72.45
7D
-0.6%
1Y
91.8%
Sierra Oncology
Market Cap: US$1.3b
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs.
SRRA
US$54.99
7D
0.06%
1Y
179.4%
Aprea Therapeutics
Market Cap: US$7.4m
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
APRE
US$1.32
7D
-3.6%
1Y
-61.5%